These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 15183629

  • 1. The nicotinic acid receptor--a new mechanism for an old drug.
    Karpe F, Frayn KN.
    Lancet; 2004 Jun 05; 363(9424):1892-4. PubMed ID: 15183629
    [Abstract] [Full Text] [Related]

  • 2. Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue.
    Oh YT, Oh KS, Choi YM, Jokiaho A, Donovan C, Choi S, Kang I, Youn JH.
    Am J Physiol Endocrinol Metab; 2011 Jun 05; 300(6):E1012-21. PubMed ID: 21386057
    [Abstract] [Full Text] [Related]

  • 3. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect.
    Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S.
    Nat Med; 2003 Mar 05; 9(3):352-5. PubMed ID: 12563315
    [Abstract] [Full Text] [Related]

  • 4. Niacin stimulates adiponectin secretion through the GPR109A receptor.
    Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RL.
    Am J Physiol Endocrinol Metab; 2009 Mar 05; 296(3):E549-58. PubMed ID: 19141678
    [Abstract] [Full Text] [Related]

  • 5. Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid.
    Dhalla AK, Santikul M, Smith M, Wong MY, Shryock JC, Belardinelli L.
    J Pharmacol Exp Ther; 2007 Apr 05; 321(1):327-33. PubMed ID: 17204748
    [Abstract] [Full Text] [Related]

  • 6. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.
    Lukasova M, Hanson J, Tunaru S, Offermanns S.
    Trends Pharmacol Sci; 2011 Dec 05; 32(12):700-7. PubMed ID: 21944259
    [Abstract] [Full Text] [Related]

  • 7. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.
    Carlson LA.
    J Intern Med; 2005 Aug 05; 258(2):94-114. PubMed ID: 16018787
    [Abstract] [Full Text] [Related]

  • 8. [Nicotinic acid and derivatives for therapy of hyperlipoproteinemia].
    Ishikawa T.
    Nihon Rinsho; 1994 Dec 05; 52(12):3292-7. PubMed ID: 7853725
    [Abstract] [Full Text] [Related]

  • 9. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
    Offermanns S.
    Trends Pharmacol Sci; 2006 Jul 05; 27(7):384-90. PubMed ID: 16766048
    [Abstract] [Full Text] [Related]

  • 10. Adipose Tissue Free Fatty Acid Storage In Vivo: Effects of Insulin Versus Niacin as a Control for Suppression of Lipolysis.
    Ali AH, Mundi M, Koutsari C, Bernlohr DA, Jensen MD.
    Diabetes; 2015 Aug 05; 64(8):2828-35. PubMed ID: 25883112
    [Abstract] [Full Text] [Related]

  • 11. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia.
    Julius U.
    Exp Clin Endocrinol Diabetes; 2003 Aug 05; 111(5):246-50. PubMed ID: 12951628
    [Abstract] [Full Text] [Related]

  • 12. Fatty acids and the risk of death during acute myocardial ischaemia.
    Oliver MF.
    Clin Sci (Lond); 2015 Mar 05; 128(6):349-55. PubMed ID: 25456320
    [Abstract] [Full Text] [Related]

  • 13. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA, O'Connell DP, Lamon-Fava S, LeBlanc DF, Kuang YL, Schaefer EJ, Coppage AL, Benedict CR, Kiritsy CP, Bachovchin WW.
    Metabolism; 2013 Dec 05; 62(12):1840-9. PubMed ID: 24035454
    [Abstract] [Full Text] [Related]

  • 14. Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists.
    Carballo-Jane E, Gerckens LS, Luell S, Parlapiano AS, Wolff M, Colletti SL, Tata JR, Taggart AK, Waters MG, Richman JG, McCann ME, Forrest MJ.
    J Pharmacol Toxicol Methods; 2007 Dec 05; 56(3):308-16. PubMed ID: 17643322
    [Abstract] [Full Text] [Related]

  • 15. On the suppression of plasma nonesterified fatty acids by insulin during enhanced intravascular lipolysis in humans.
    Carpentier AC, Frisch F, Cyr D, Généreux P, Patterson BW, Giguère R, Baillargeon JP.
    Am J Physiol Endocrinol Metab; 2005 Nov 05; 289(5):E849-56. PubMed ID: 15972273
    [Abstract] [Full Text] [Related]

  • 16. Identification of a nicotinic acid receptor: is this the molecular target for the oldest lipid-lowering drug?
    Pike NB, Wise A.
    Curr Opin Investig Drugs; 2004 Mar 05; 5(3):271-5. PubMed ID: 15083592
    [Abstract] [Full Text] [Related]

  • 17. Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug.
    Kang I, Kim SW, Youn JH.
    J Clin Endocrinol Metab; 2011 Oct 05; 96(10):3048-55. PubMed ID: 21816780
    [Abstract] [Full Text] [Related]

  • 18. New evidence for nicotinic acid treatment to reduce atherosclerosis.
    Montecucco F, Quercioli A, Dallegri F, Viviani GL, Mach F.
    Expert Rev Cardiovasc Ther; 2010 Oct 05; 8(10):1457-67. PubMed ID: 20936932
    [Abstract] [Full Text] [Related]

  • 19. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway.
    Zierath JR, Livingston JN, Thörne A, Bolinder J, Reynisdottir S, Lönnqvist F, Arner P.
    Diabetologia; 1998 Nov 05; 41(11):1343-54. PubMed ID: 9833943
    [Abstract] [Full Text] [Related]

  • 20. Free fatty acids and insulin resistance.
    Delarue J, Magnan C.
    Curr Opin Clin Nutr Metab Care; 2007 Mar 05; 10(2):142-8. PubMed ID: 17285001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.